Huons Meditech surpasses 20,000 units sold in Dermashine product line

Huons Meditech, a medical device manufacture under Huons Group, said on Friday  its cumulative global sales of Dermashine product line have exceeded 20,000 units since its launch in 2011.

The Dermashine Series, which includes the Dermashine, Dermashine Balance, and Dermashine Pro models, has become the preferred choice for mesotherapy applications worldwide, the company said.

Domestically, over 7,000 units have been installed in top-tier dermatology clinics, plastic surgery centers, and aesthetic facilities, while international sales have surpassed 13,000 units, driven by strong demand in markets such as China and Southeast Asia, according to Huons Meditech.

Known for its precision, the Dermashine series features an advanced automatic injection system that delivers highly concentrated hyaluronic acid to the skin. This proprietary technology has been key to creating the "water-light" skin trend, elevating aesthetic standards in the Korean beauty market. "Water-light skin" refers to a glowing, hydrated, and dewy complexion that gives the appearance of skin that is plump and smooth.

Huons Meditech's recent innovations include the introduction of a premium needle designed to minimize injection pain and reduce material leakage. Additionally, with the growing popularity of polymer-based skin boosters like PDLA (Poly-D-Lactic Acid) and PLLA (Poly-L-Lactic Acid), Huons Meditech is preparing to launch the Dermashine Duo RF in early 2025. 

“Our commitment is to provide differentiated and accessible medical aesthetics solutions tailored to market needs,” said Lee Jin-suk, CEO of Huons Meditech. “As we continue to innovate, our focus remains on solidifying Huons Meditech’s position as a global leader in medical device manufacturing.”